This paper reviews a series of mechanisms whereby company marketing of antidepressants (including those used in the treatment of suicidality) & anxiety drugs can both transform the perceptions of physicians & shape the experiences of those seeking treatment & the self-understanding of those not in treatment. The author argues that the result of various marketing manoeuvres has been a transformation & growth in disorders tailor-made to fit ever more visible drugs. (63 refs)